We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Medtech Insight is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Replidyne reverse merges with Cardiovascular Systems
13 Nov 2008
Executive Summary
Right after withdrawing from its initial public offering, Cardiovascular Systems Inc. announced it has agreed to be acquired by infectious disease therapeutics developer Replidyne in a reverse merger. Once the stock swap is completed, CSI's shareholders will own 83% of the combined company, which will retain CSI's name.
Deal Industry
Biotechnology
Pharmaceuticals
Deal Status
Final
Deal Type
Acquisition
Full Acquisition
Payment Includes Stock
Reverse Acquisition
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?